Latest News and Press Releases

ROCKVILLE, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...

ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...

First quarter total revenue of $95.0 million, an 11% increase over 2019First quarter net product sales of $92.5 million, an 11% increase over 2019First quarter operating earnings of $29.0 million, a...

 Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipelineDiversifies revenue and operating cash flow base with 2019 net sales of approximately $150 million...

ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...

Companies to Collaborate on Phase II Development for NV-5138 in DepressionNV-5138 is a Novel First-in-Class Activator of mTORC1Supernus Receives Exclusive Option to License or Acquire NV-5138 Prior to...

ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...

ROCKVILLE, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...

Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively.Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million,...

ROCKVILLE, Md., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...